APA (7th ed.) Citation

Badri, P., Jiang, X., Borodovsky, A., Najafian, N., Kim, J., Clausen, V. A., . . . Robbie, G. J. (2021). Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clinical pharmacokinetics, 60(3), 365-378. https://doi.org/10.1007/s40262-020-00940-9

Chicago Style (17th ed.) Citation

Badri, Prajakta, Xuemin Jiang, Anna Borodovsky, Nader Najafian, Jae Kim, Valerie A. Clausen, Varun Goel, Bahru Habtemariam, and Gabriel J. Robbie. "Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria." Clinical Pharmacokinetics 60, no. 3 (2021): 365-378. https://doi.org/10.1007/s40262-020-00940-9.

MLA (9th ed.) Citation

Badri, Prajakta, et al. "Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria." Clinical Pharmacokinetics, vol. 60, no. 3, 2021, pp. 365-378, https://doi.org/10.1007/s40262-020-00940-9.